GlassScriptPhysician profile
Dien T Le
NPI 1679508832
$2,148.64
in general payments reported to CMS, 2019-2025
14 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.08 · 2020: $59.66 · 2021: $126 · 2022: $827 · 2023: $157 · 2024: $664 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $556.34 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Johnson & Johnson Vision Care, INC. | $364.63 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $303.92 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $210.77 | 2021-2024 | Dailies Total1, Precision 1, Total30 |
| Topcon Healthcare, INC. | $170.43 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $155.54 | 2022 | |
| Biotissue Holdings INC. | $147.13 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $124.97 | 2020-2023 | |
| Astellas Pharma US INC | $27.33 | 2024 | Izervay |
| Allergan, INC. | $21.18 | 2021 | |
| Abb Con-Cise Optical Group LLC | $20.08 | 2019 | |
| Glaukos Corporation | $17.76 | 2023 | |
| Oyster Point Pharma, INC. | $15.49 | 2024 | Ryzumvi, Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dien Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.